<DOC>
	<DOCNO>NCT00380354</DOCNO>
	<brief_summary>This study evaluate efficacy safety GSK256066 treatment subject mild bronchial asthma , use number clinical biological marker efficacy .</brief_summary>
	<brief_title>Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>6- ( ( 3- ( ( dimethylamino ) carbonyl ) phenyl ) sulfonyl ) -8-methyl-4- ( ( 3-methyloxyphenyl ) amino ) -3-quinolinecarboxamide</mesh_term>
	<criteria>Inclusion criterion Documented history bronchial asthma , first diagnose least 6 month prior screen visit currently treat intermittent shortacting beta agonist therapy inhalation . Prebronchodilator FEV1 &gt; 75 % predict screening . Nonsmoker Demonstration positive reaction least one allergen battery allergen ( include house dust mite , grass pollen cat hair skin prick test screening , within 12 month study start . Have Asthmatic response Able willing give write informed consent take part study . Available complete study measurement . Exclusion criterion : History cardiovascular disease Clinically significant abnormality safety laboratory analysis screen include subject great `` trace urine protein level '' follow urinalysis screen . History hayfever The subject test positive hepatitis C antibody hepatitis B surface antigen . The subject test positive HIV antibody . The subject positive drug abuse test . Subjects weigh less 50kg exclude participate study . The subject participate study new molecular entity previous 3 month . History unable tolerate complete methacholine , and/or allergen challenge test . There risk noncompliance study medication study procedure . History blood donation ( 450 mL ) within 2 month start clinical study . The subject regularly drink 28 unit alcohol week male , 21 unit per week female . One unit alcohol define medium ( 125 ml ) glass wine , half pint ( 250 ml ) beer one measure ( 24 ml ) spirit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>allergen</keyword>
	<keyword>methacholine</keyword>
	<keyword>GSK256066</keyword>
	<keyword>mild asthmatic</keyword>
	<keyword>repeat dose</keyword>
	<keyword>challenge</keyword>
	<keyword>late asthmatic response</keyword>
</DOC>